CASR and hypercalcemia disease: In summary, we have established a mouse model for FHH2 and have shown the in vivo efficacy of cinacalcet in reducing plasma calcium and PTH concentrations, thereby illustrating the potential utility of this CaSR allosteric modulator for the treatment of hypercalcemia in patients with FHH2.